Pharmacokinetics and safety of the antitumor drug everolimus in healthy Chinese subjects: a single-dose, open-label, randomized, two-sequence, two-period crossover, phase I bioequivalence study
Authors
Yu‐Ting Liu (ORCID: https://orcid.org/0000-0003-3738-7125)
Xiao‐Yi Yi (ORCID: https://orcid.org/0000-0001-5482-9496)
Clinical Trial Center, China Medical University Hospital
Education Department of Jiangxi Province
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Pharmacokinetics and safety of the antitumor drug everolimus in healthy Chinese subjects: a single-dose, open-label, randomized, two-sequence, two-period crossover, phase I bioequivalence study
Yu‐Ting Liu, Xiao‐Yi Yi, Xiaodan Chen, Xiaosong Wang et al.
Journal
Frontiers in Pharmacology
Topics
PI3K/AKT/mTOR signaling in cancer
article
Pharmacokinetics and safety of the antitumor drug everolimus in healthy Chinese subjects: a single-dose, open-label, randomized, two-sequence, two-period crossover, phase I bioequivalence study
Nanchang University (CN), First Affiliated Hospital of Jiangxi Medical College (CN), Jiangxi Provincial Cancer Hospital (CN), Second Affiliated Hospital of Nanchang University (CN), Second Hospital of Nanchang (CN)
Funders
Clinical Trial Center, China Medical University Hospital, Education Department of Jiangxi Province